Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DLC1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DLC1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DLC1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DLC1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DLC1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0051494110 | Thyroid | ATC | negative regulation of cytoskeleton organization | 76/6293 | 163/18723 | 3.68e-04 | 2.27e-03 | 76 |
GO:005105812 | Thyroid | ATC | negative regulation of small GTPase mediated signal transduction | 31/6293 | 56/18723 | 6.60e-04 | 3.74e-03 | 31 |
GO:003530613 | Thyroid | ATC | positive regulation of dephosphorylation | 32/6293 | 59/18723 | 8.74e-04 | 4.72e-03 | 32 |
GO:004001316 | Thyroid | ATC | negative regulation of locomotion | 160/6293 | 391/18723 | 1.36e-03 | 7.07e-03 | 160 |
GO:000716225 | Thyroid | ATC | negative regulation of cell adhesion | 127/6293 | 303/18723 | 1.45e-03 | 7.47e-03 | 127 |
GO:004658012 | Thyroid | ATC | negative regulation of Ras protein signal transduction | 27/6293 | 49/18723 | 1.58e-03 | 7.99e-03 | 27 |
GO:003033616 | Thyroid | ATC | negative regulation of cell migration | 142/6293 | 344/18723 | 1.64e-03 | 8.22e-03 | 142 |
GO:005127117 | Thyroid | ATC | negative regulation of cellular component movement | 150/6293 | 367/18723 | 1.99e-03 | 9.54e-03 | 150 |
GO:200014617 | Thyroid | ATC | negative regulation of cell motility | 147/6293 | 359/18723 | 2.01e-03 | 9.60e-03 | 147 |
GO:001095033 | Thyroid | ATC | positive regulation of endopeptidase activity | 79/6293 | 179/18723 | 2.09e-03 | 9.86e-03 | 79 |
GO:003502314 | Thyroid | ATC | regulation of Rho protein signal transduction | 42/6293 | 86/18723 | 2.43e-03 | 1.13e-02 | 42 |
GO:004328031 | Thyroid | ATC | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 58/6293 | 129/18723 | 4.70e-03 | 1.93e-02 | 58 |
GO:00108127 | Thyroid | ATC | negative regulation of cell-substrate adhesion | 33/6293 | 68/18723 | 7.60e-03 | 2.97e-02 | 33 |
GO:200105632 | Thyroid | ATC | positive regulation of cysteine-type endopeptidase activity | 64/6293 | 148/18723 | 8.98e-03 | 3.39e-02 | 64 |
GO:003502413 | Thyroid | ATC | negative regulation of Rho protein signal transduction | 13/6293 | 22/18723 | 1.25e-02 | 4.38e-02 | 13 |
GO:000691922 | Thyroid | ATC | activation of cysteine-type endopeptidase activity involved in apoptotic process | 36/6293 | 78/18723 | 1.43e-02 | 4.92e-02 | 36 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DLC1 | SNV | Missense_Mutation | | c.2960N>C | p.Gly987Ala | p.G987A | Q96QB1 | protein_coding | deleterious(0) | possibly_damaging(0.449) | TCGA-A2-A0D0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
DLC1 | SNV | Missense_Mutation | rs773001160 | c.1724G>A | p.Gly575Asp | p.G575D | Q96QB1 | protein_coding | deleterious(0.04) | benign(0.018) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
DLC1 | SNV | Missense_Mutation | rs762750959 | c.1723G>A | p.Gly575Ser | p.G575S | Q96QB1 | protein_coding | tolerated(0.28) | benign(0) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
DLC1 | SNV | Missense_Mutation | | c.2533N>A | p.Gly845Ser | p.G845S | Q96QB1 | protein_coding | tolerated(0.11) | probably_damaging(1) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DLC1 | SNV | Missense_Mutation | novel | c.4058N>G | p.Glu1353Gly | p.E1353G | Q96QB1 | protein_coding | deleterious(0) | benign(0.41) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DLC1 | SNV | Missense_Mutation | | c.3983N>T | p.Cys1328Phe | p.C1328F | Q96QB1 | protein_coding | tolerated(0.15) | possibly_damaging(0.803) | TCGA-AO-A03V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
DLC1 | SNV | Missense_Mutation | | c.305C>A | p.Ala102Asp | p.A102D | Q96QB1 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.905) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
DLC1 | SNV | Missense_Mutation | | c.3205N>C | p.Asp1069His | p.D1069H | Q96QB1 | protein_coding | deleterious(0) | benign(0.354) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DLC1 | SNV | Missense_Mutation | | c.2882N>A | p.Pro961His | p.P961H | Q96QB1 | protein_coding | deleterious(0.02) | possibly_damaging(0.525) | TCGA-D8-A1JF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
DLC1 | SNV | Missense_Mutation | rs745492706 | c.878N>A | p.Gly293Asp | p.G293D | Q96QB1 | protein_coding | tolerated_low_confidence(0.35) | benign(0.001) | TCGA-D8-A1XF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |